The role of stem-cell transplantation in the treatment of marginal zone lymphoma. Issue 1 (March 2017)

• Record Type: Journal Article
• Authors: Shimoni, Avichai
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 30:Issue 1/2(2017)
• Page Start: 166
• Page End: 171
• Publication Date: 2017-03
• Subjects: Marginal-zone lymphoma -- Stem-cell transplantation; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2016.08.027
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: High-dose chemotherapy and autologous stem-cell transplantation (ASCT) is standard therapy in relapsed/refractory aggressive lymphoma. The optimal therapy of relapsed/refractory disseminated marginal-zone lymphoma (MZL) has not been defined. Limited data on ASCT in this setting suggests outcomes are similar to what is expected in follicular lymphoma. International guidelines suggest that ASCT should be considered in follicular lymphoma in second or subsequent remission, in particular in high-risk disease, or following disease transformation. These guidelines can be extrapolated to MZL. ASCT is not considered curative but a subset of patients achieve very long remissions. The major concern is the occurrence of secondary malignancies possibly related to total-body irradiation. Allogeneic SCT is usually considered after failure of ASCT, but can also be considered upfront in younger patients seeking curative approach. The introduction of novel/targeted therapies may change the role and timing SCT may have in the treatment algorithm of indolent lymphomas.